Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
出版年份 2017 全文链接
标题
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
作者
关键词
-
出版物
LEUKEMIA
Volume 32, Issue 2, Pages 313-322
出版商
Springer Nature
发表日期
2017-09-12
DOI
10.1038/leu.2017.257
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor
- (2016) Nadine Sandhöfer et al. Scientific Reports
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo
- (2015) P Arreba-Tutusaus et al. LEUKEMIA
- FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
- (2015) C C Smith et al. LEUKEMIA
- Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
- (2015) C Krupka et al. LEUKEMIA
- Antileukemic Activity of 2-Deoxy-D-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations
- (2015) C. Larrue et al. MOLECULAR CANCER THERAPEUTICS
- Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia
- (2015) Michael Durben et al. MOLECULAR THERAPY
- An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging
- (2015) Binje Vick et al. PLoS One
- Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function
- (2014) D. Wolleschak et al. HAEMATOLOGICA
- Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia
- (2013) S. Opatz et al. BLOOD
- CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
- (2013) C. Krupka et al. BLOOD
- FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
- (2013) Michael R. Grunwald et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
- (2013) Kerstin Maria Kampa-Schittenhelm et al. Molecular Cancer
- Adaptive immune activation: glycosylation does matter
- (2013) Margreet A Wolfert et al. Nature Chemical Biology
- Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
- (2013) Karthika Natarajan et al. PLoS One
- FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
- (2013) M. Levis Hematology-American Society of Hematology Education Program
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases
- (2012) Harald Polzer et al. EXPERIMENTAL HEMATOLOGY
- Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia
- (2012) M Hofmann et al. LEUKEMIA
- Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model
- (2011) Perry M. Chan Protein & Cell
- FLT3 as a therapeutic target in AML: still challenging after all these years
- (2010) T. Kindler et al. BLOOD
- Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia
- (2010) Fabio P. S. Santos et al. CANCER
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug resistance in mutant FLT3-positive AML
- (2010) E Weisberg et al. ONCOGENE
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation
- (2009) S. Metzelder et al. BLOOD
- A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
- (2009) F. Breitenbuecher et al. BLOOD
- Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality
- (2009) D. Schmidt-Arras et al. BLOOD
- FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
- (2009) N. von Bubnoff et al. CANCER RESEARCH
- Mechanisms of resistance to FLT3 inhibitors
- (2009) S. Haihua Chu et al. DRUG RESISTANCE UPDATES
- Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes
- (2009) Chunaram Choudhary et al. MOLECULAR CELL
- Abnormal Localization and Accumulation of FLT3-ITD, a Mutant Receptor Tyrosine Kinase Involved in Leukemogenesis
- (2008) Sina Koch et al. CELLS TISSUES ORGANS
- FLT3 inhibitors for the treatment of autoimmune disease
- (2008) Katharine A Whartenby et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation
- (2008) W Zhao et al. LEUKEMIA
- Targeting FLT3 for the Treatment of Leukemia
- (2008) Donald Small SEMINARS IN HEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now